PVI
NKTR icon

Pura Vida Investments’s Nektar Therapeutics NKTR Stock Holding History

Pura Vida Investments’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-18,905
Closed -$3.83M – 267
2021
Q4 		$3.83M Buy
+18,905
New +$4.1M 0.14% 124

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Pura Vida Investments's NKTR Position: Q4 2021 in Review

Pura Vida Investments sold out of Nektar Therapeutics (NKTR) in Q4 2021, closing a stake of 14,636 shares — an estimated $3.18M sold.

Pura Vida Investments first reported a position in NKTR in Q4 2020 and held it in 2 quarters. The position peaked at $3.94M in Q3 2021. 241 funds tracked by Wall St. Rank hold NKTR as of Q4 2021.

  • Pura Vida Investments reported no remaining Nektar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Pura Vida Investments sold 14,636 Nektar Therapeutics shares in Q4 2021, an estimated $3.18M.
  • Pura Vida Investments first reported a position in Nektar Therapeutics in Q4 2020 and held it in 2 quarters.
  • Pura Vida Investments's Nektar Therapeutics position peaked at $3.94M in Q3 2021.
  • 241 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2021.

Based on Pura Vida Investments's 13F filing for Q4 2021, filed 14 Feb 2022.